Compare SPT & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPT | AGMB |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.7M | 576.2M |
| IPO Year | 2019 | 2024 |
| Metric | SPT | AGMB |
|---|---|---|
| Price | $9.29 | $10.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $11.75 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.0M | 150.3K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $457,547,000.00 | N/A |
| Revenue This Year | $8.86 | N/A |
| Revenue Next Year | $8.04 | $17.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.72 | N/A |
| 52 Week Low | $4.92 | $8.75 |
| 52 Week High | $13.25 | $17.82 |
| Indicator | SPT | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 31.50 |
| Support Level | $9.22 | $9.54 |
| Resistance Level | $11.85 | $12.53 |
| Average True Range (ATR) | 0.51 | 1.07 |
| MACD | -0.24 | -0.28 |
| Stochastic Oscillator | 12.45 | 5.13 |
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.